Dr. Avital Harari is interested in translational and outcomes studies of patients with benign and malignant tumors of the adrenal, thyroid, and parathyroid glands, as well as the neuroendocrine pancreas and familial endocrine disorders (such as multiple endocrine neoplasia).
Selected Cancer-Related Publications:
Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012 Mar;13(1):11-23.
Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, Shen W, Gosnell J, Duh QY, Clark O. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011 Dec;96(12):3679-86. Epub 2011 Sep 21.
Harari A, Inabnet WB 3rd. Malignant pheochromocytoma: a review. Am J Surg. 2011 May;201(5):700-8. Epub 2010 Sep 27.
Harari A, Mitmaker E, Grogan RH, Lee J, Shen W, Gosnell J, Clark O, Duh QY. Primary hyperparathyroidism patients with positive preoperative sestamibi scan and negative ultrasound are more likely to have posteriorly located upper gland adenomas (PLUGs). Ann Surg Oncol. 2011 Jun;18(6):1717-22. Epub 2011 Jan 5.
Harari A, Zarnegar R, Lee J, Kazam E, Inabnet WB 3rd, Fahey TJ 3rd. Computed tomography can guide focused exploration in select patients with primary hyperparathyroidism and negative sestamibi scanning. Surgery. 2008 Dec;144(6):970-6; discussion 976-9.